Form 8-K - Current report:
SEC Accession No. 0001493152-23-020163
Filing Date
2023-06-06
Accepted
2023-06-05 19:02:10
Documents
14
Period of Report
2023-06-01
Items
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 45819
2 ex3-1.htm EX-3.1 10278
  Complete submission text file 0001493152-23-020163.txt   278465

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE lixt-20230601.xsd EX-101.SCH 3990
4 XBRL DEFINITION FILE lixt-20230601_def.xml EX-101.DEF 26651
5 XBRL LABEL FILE lixt-20230601_lab.xml EX-101.LAB 36769
6 XBRL PRESENTATION FILE lixt-20230601_pre.xml EX-101.PRE 25275
8 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 5671
Mailing Address 248 ROUTE 25A NO. 2 EAST SETAUKET NY 11733
Business Address 248 ROUTE 25A NO. 2 EAST SETAUKET NY 11733 310 203 2902
LIXTE BIOTECHNOLOGY HOLDINGS, INC. (Filer) CIK: 0001335105 (see all company filings)

EIN.: 202903526 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39717 | Film No.: 23994426
SIC: 2834 Pharmaceutical Preparations